- Home
- FUBO vs AUTL Comparison
FUBO vs AUTL Comparison
Compare FUBO & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FUBO | AUTL |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.3M | 431.2M |
| IPO Year | 2011 | 2025 |
Fundamental Metrics
Financial Performance| Metric | FUBO | AUTL |
|---|---|---|
| Price | $12.59 | $1.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $28.40 | $8.50 |
| AVG Volume (30 Days) | ★ 4.7M | 1.8M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.08 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,271,000.00 | ★ $10,120,000.00 |
| Revenue This Year | $45.37 | $84.74 |
| Revenue Next Year | $6.47 | $65.76 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10317.07 | 496.00 |
| 52 Week Low | $1.02 | $1.15 |
| 52 Week High | $14.21 | $2.70 |
Technical Indicators
Market Signals| Indicator | FUBO | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 73.32 | 62.66 |
| Support Level | $3.17 | $1.25 |
| Resistance Level | $14.05 | $1.69 |
| Average True Range (ATR) | 1.07 | 0.09 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 77.20 | 98.74 |
Price Performance
Historical ComparisonAbout FUBO fuboTV Inc.
FuboTV Inc is a sports-first, live TV streaming company offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, FuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. It offers subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality suited to their preferences. The company has one operating segment, the streaming business. Geographically, the company generates a majority of its revenue from the United States and also has a presence in other markets.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.